Chronic Low-back Pain
Conditions
Brief summary
The goal of this observational study is to better understand the role of the brain in chronic low back pain patients.
Detailed description
Chronic pain affects millions of people worldwide, and the main cardinal sign of any arthritis condition is pain. Several arthritis conditions can cause chronic low back pain (CLBP).The mechanisms that contribute to CLBP are not yet fully understood, but considering the role of the brain in the context of chronic pain, it is only logical to investigate structural and functional brain properties in CLBP, in order to improve diagnosis and treatment of this condition.
Interventions
OTHERNo intervention
No intervention will be given in our study since, the investigators are recruiting people who will receive already a facet thermal ablation.
Sponsors
Université de Sherbrooke
Study design
Observational model
OTHER
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Inclusion criteria
* Low back pain (≥ 6 months) with or without pain radiating to the legs or radiating to the neck * Positive medial branch blocks, suggesting that the pain originates from the lumbar facet joints * Average pain intensity of ≥ 3/10 in the 24-hour period before the initial visit * Pain primarily localized in the lower back
Exclusion criteria
* Inadequate pain relief or relief of less than three months following selective thermoablation of medial lumbar branches by radiofrequency * Neurological, cardiovascular, or pulmonary disorders * Comorbid pain syndrome * History of surgical intervention in the back * A corticosteroid infiltration within the past year * Pregnancy (current or planned during the course of the study) * Contra-indication to Magnetic Resonance Imaging (MRI)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change of Grey matter volume | Change from Baseline (1 week, 2 months and 4 months before their treatment) and after their treatment (at 2 months and 4 months post treatment) | Grey matter volume (milliliters cube) will be measured by acquiring a T1weighted (T1w) image using Magnetic Resonance Imaging. |
| Change of Blood-oxygen level dependent (BOLD) response | Change from Baseline (1 week, 2 months and 4 months before their treatment) and after their treatment (at 2 months and 4 months post treatment) | Blood-oxygen level dependent (BOLD) response will be measured by using functional Magnetic Resonance Imaging (fMRI). |
| Change of Microstructural and connectivity properties of white matter tracts | Change from Baseline (1 week, 2 months and 4 months before their treatment) and after their treatment (at 2 months and 4 months post treatment) | Microstructural and connectivity properties will be measured by using diffusion Magnetic Resonance Imaging (dMRI). |
| Change of Brain's arteries system | Change from Baseline (1 week, 2 months and 4 months before their treatment) and after their treatment (at 2 months and 4 months post treatment) | Brain vasculature will be measured by using Time-of-Flight Magnetic Resonance Angiography (ToF MRA). |
| Change of Brain's venous system | Change from Baseline (1 week, 2 months and 4 months before their treatment) and after their treatment (at 2 months and 4 months post treatment) | Brain vasculature will be measured by using Susceptibility Weighted Imaging (SWI). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change of Anxiety score | Change from Baseline (1 week, 2 months and 4 months before their treatment) and after their treatment (at 2 months and 4 months post treatment) | The investigators will use the State-Trait Anxiety Inventory (STAI-S/T). Measured on a 4-point Likert-scale (0 = not at all to 3 = all the time). |
| Change of Depression score | Change from Baseline (1 week, 2 months and 4 months before their treatment) and after their treatment (at 2 months and 4 months post treatment) | The investigators will use the Beck Depression Inventory (BDI). Measured on a 4-point Likert-scale (0 = less symptoms to 3 = more severe symptoms). Higher score means worse outcome. |
| Change of Fear of movement score | Change from Baseline (1 week, 2 months and 4 months before their treatment) and after their treatment (at 2 months and 4 months post treatment) | The investigators will use the Tampa Scale of Kinesiophobia - short form (TSK-SF).Measured on a 4-point Likert-scale (0 = Strongly Disagree to 3 = Strongly Agree). Higher score means worse outcome. |
| Change of Functional disability score | Change from Baseline (1 week, 2 months and 4 months before their treatment) and after their treatment (at 2 months and 4 months post treatment) | The investigators will use the Oswestry Disability Index (ODI). Measured on a 6-point Likert Scale (0 = less symptoms to 5 = more severe symptoms). Higher score means worse outcome. |
| Change of Insomnia severity score | Change from Baseline (1 week, 2 months and 4 months before their treatment) and after their treatment (at 2 months and 4 months post treatment) | The investigators will use the Insomnia severity Index (ISI). Measured on a 5-point Likert scale (0 = not at all to 4 = extremely). Higher score means worse outcome. |
| Change of Pain Severity score | Change from Baseline (1 week, 2 months and 4 months before their treatment) and after their treatment (at 2 months and 4 months post treatment) | The investigators will use the Brief Pain Inventory-short form (BPI-SF). Measured on a numerical rating scale (0 = no pain to 10 = worst pain imaginable). Higher score means worse outcome. |
| Patient Expectations score | This will be acquired 1 week before their treatment | The investigators will use the EXPECT Questionnaire. Measured on numerical rating scale (0 = no change to 10 = complete relief). Higher score means better outcome. |
| Change of Global Impression score | Change from Baseline (at 2 months post treatment) and after 2 months (at 4 months post treatment) | The investigators will use the Patients' Global Impression of Change (PGIC) scale. Measured on numerical rating scale (0 = no change to 10 = complete relief). Higher score means better outcome. |
| Change Central sensitization component score | Change from Baseline (1 week, 2 months and 4 months before their treatment) and after their treatment (at 2 months and 4 months post treatment) | The investigators will use the Central Sensitization Inventory - short form (CSI-SF). Measured on a 5-point Likert-scale (0 = never to 4 = always). Higher score means worse outcome. |
| Patient Gender score | Change from Baseline (1 week, 2 months and 4 months before their treatment) and after their treatment (at 2 months and 4 months post treatment) | The investigators will use a Short Gender Questionnaire (SGQ). Measured on a 5-point Likert-scale (1 = not at all to 5 = extremely). |
| Change Polygenic methylation score | Change from Baseline (1 week, 2 months and 4 months before their treatment) and after their treatment (at 2 months and 4 months post treatment) | The investigators will acquire a saliva sample using a DNA kit to perform epigenetic analysis. |
| Number of traumatic events | Change from Baseline (4 weeks before their treatment) and after their treatment (at 4 months post treatment) | The investigators will use the Life Events Checklist (LEC). We will count the number of traumatic events. |
| Change of Pain Interference score | Change from Baseline (1 week, 2 months and 4 months before their treatment) and after their treatment (at 2 months and 4 months post treatment) | The investigators will use the Brief Pain Inventory-short form (BPI-SF). Measured on a numerical rating scale (0 = no interference to 10 = complete interference). Higher score means worse outcome. |
| Change of Pain Catastrophizing score | Change from Baseline (1 week, 2 months and 4 months before their treatment) and after their treatment (at 2 months and 4 months post treatment) | The investigators will use the Pain Catastrophizing-short form (PCS-SF). Measured on a 5-point Likert-scale (0 = not at all to 4 = all the time). Higher score means worse outcome. |
| Change of Neuropathic pain components score | Change from Baseline (1 week, 2 months and 4 months before their treatment) and after their treatment (at 2 months and 4 months post treatment) | The investigators will use the Pain detect. Seven items are measured on a rated on a 6-point Likert Scale (0 = not at all to 5 = very strongly). Higher score means worse outcome. 1 item based on pain behavior pattern score (-1, 0 or 1) and 1 item based on a radiation score (0 or 2). |
| Change of Global function score | Change from Baseline (1 week, 2 months and 4 months before their treatment) and after their treatment (at 2 months and 4 months post treatment) | The investigators will use the Pain Outcomes Questionnaire (POQ). Measured on a numeric rating scale (0 = less symptoms to 10= more severe symptoms). Higher score means worse outcome. |
Countries
Canada
Contacts
Primary ContactPascal Tétreault, PhD
Backup ContactMarylie Martel, PhD
Outcome results
None listed